Document:

Change in Control Cash Severance Agreement, C. Douglas White

 Exhibit 10.13 
 White 
 BG MEDICINE, INC. 
 CHANGE OF CONTROL CASH SEVERANCE AGREEMENT 

 THIS Change of Control Cash Severance Agreement (the “Agreement”) is dated as of February 16,
2009 by and between BG Medicine, Inc., a Delaware corporation (the “Company”), and C. Douglas White (the “Employee”). 
 WHEREAS, the Board of Directors of the Company (the “Board”) has determined that it is in the best interests of the Company and its shareholders to assure that the Company will have the
continued dedication of the Employee, notwithstanding the possibility, threat, or occurrence of a Change of Control (as defined below) of the Company. The Board believes it is imperative to diminish the inevitable distraction of the Employee by
virtue of the personal uncertainties and risks created by a pending or threatened Change of Control and to encourage the Employee’s full attention and dedication to the Company currently and in the event of any threatened or pending Change of
Control, and to provide the Employee with compensation and benefits arrangements upon a Change of Control which ensure that the compensation and benefits expectations of the Employee will be satisfied and which are competitive with those of other
corporations. Therefore, in order to accomplish these objectives, the Board has caused the Company to enter into this Agreement; 
 NOW, THEREFORE, in consideration of the covenants and agreements set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby mutually acknowledged, the parties hereto covenant and agree as
follows: 
 1. Certain Definitions. For the purpose of this Agreement and unless defined elsewhere in the Agreement, the
following terms shall have the meanings ascribed to them below. 
 (a) “Cause” means conduct involving one or more of
the following: (i) the substantial and continuing failure of the Employee, after notice thereof, to render services to the Company in accordance with the terms or requirements of his or her employment; (ii) disloyalty, gross negligence,
willful misconduct, dishonesty, fraud or breach of fiduciary duty to the Company; (iii) deliberate disregard of the rules or policies of the Company, or breach of an employment or other agreement with the Company, which results in direct or
indirect loss, damage or injury to the Company; (iv) the unauthorized disclosure of any trade secret or confidential information of the Company; or (v) the commission of an act which constitutes unfair competition with the Company or which
induces any customer or supplier to breach a contract with the Company. 
 (b) “Change of Control” means the sale of
the Company by merger, in which the shareholders of the Company in their capacity as such no longer own a majority of the outstanding equity securities of the Company (or its successor) or any sale of all or substantially all of the assets or
capital stock of the Company (other than in a spin-off or similar transaction) or any other acquisition of the business of the Company, as determined by the Board. For

 
purposes of this Agreement, “Change of Control” shall be interpreted in a manner, and limited to the extent necessary, so that it will not cause adverse tax consequences for either
party with respect to Section 409A of the Internal Revenue Code of 1986, as amended (“Code Section 409A”), and any successor statute, regulation and guidance thereto. 
 (c) “Change of Control Payment” means (i) a cash severance payment equal to nine (9) months of the Employee’s base
salary and (ii) a continuation of benefits for that same period, each as in effect at the time of the Payment Triggering Event. 
 (d) “Company” means the Company as hereinbefore defined and any successor to its business or assets as aforesaid which assumes and agrees to perform this Agreement by operation of law, or otherwise. 
 (e) “Comparable Employment” means employment with the successor following a Change of Control in a position that is similar in
status, scope of duties, reporting requirements, authority, responsibilities and compensation to the position held by the Employee at the Company prior to the Change of Control. 
 (f) “Good Reason” means: 
 (i) the assignment by the successor to the Employee of any duties inconsistent with the Employee’s position with the successor (including status, offices, titles and reporting requirements),
authority, duties or responsibilities, or any other action by the successor which results in a diminution in such position, authority, duties or responsibilities, excluding for this purpose an isolated, insubstantial and inadvertent action not taken
in bad faith and which is remedied by the successor promptly after receipt of notice thereof given by the Employee; 
 (ii) the successor’s requiring the Employee to be based at any office or location other than one within thirty (30) miles of the Company, as set forth in Section 3(b) hereof; or 
 (iii) any failure by the Company to comply with and satisfy Section 3(g)(iii) of this Agreement. 
 (iv) For purposes of this Agreement, “Good Reason” shall be interpreted in a manner, and limited to the extent
necessary, so that it will not cause adverse tax consequences for either party with respect to Code Section 409A, as amended, and any successor statutes, regulation and guidance thereto. 
 2. Change of Control Cash Severance Payment. 
 (a) Payment Triggering Event. In the event the Company undergoes a Change of Control transaction, then the Employee will receive the Change of Control Payment, if either (i) the Employee is
not offered Comparable Employment with the successor upon such Change of Control transaction, or (ii) the Employee begins employment with the successor, but such employment is terminated within twelve (12) months following such Change of
Control transaction by the successor without Cause or by the Employee for Good Reason (in either case, the “Payment Triggering Event”). 
  

 2 

 (b) Mechanics of Payment. Any cash portion of the Change of Control Payment payable
under this Agreement is payable in a lump sum in cash, of which one-half is payable within thirty (30) days following the Payment Triggering Event and the balance is payable upon the earlier of six (6) months following the Payment
Triggering Event or the death of the Employee. Any continuation of benefits portion of the Change of Control Payment commences upon the Payment Triggering Event and extends for the time period defined under the Change of Control Payment. 

(c) Acknowledgement. The Employee hereby acknowledges that by entering into this Agreement the Employee waives all rights he or
she may have under any other separation-related policies or agreements with the Company, provided that if the Employee has any other separation policy with the Company that would provide greater benefits to the Employee than this Agreement, then the
Employee may elect to receive benefits under such other separation-related policies or agreements in lieu of the benefits provided hereunder. 
 3. Miscellaneous. 
 (a) Governing Law. This Agreement shall be
governed by and construed in accordance with the laws of the Commonwealth of Massachusetts, without reference to principles of conflict of laws. 
 (b) Notices. All notices and other communications hereunder shall be in writing and shall be given by hand delivery to the other party or by registered or certified mail, return receipt requested,
postage prepaid, addressed as follows: 
 If to the Employee: 
 C. Douglas White 
 12972 Linden Church Road 
 Clarksville, Maryland 21029 
 If to the Company: 
 BG Medicine, Inc. 
 610 Lincoln Street North 
 Waltham, Massachusetts 02451 
 Attention: President 
 or to such other address as either party shall have furnished to the other
in writing in accordance herewith. Notices and communications shall be effective when actually received by the addressee. 
 (c)
Severability. The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement. 
 (d) Taxes. The Company may withhold from any amounts payable under this Agreement such Federal, state or local taxes as shall be
required to be withheld pursuant to any applicable law or regulation. 
  

 3 

 (e) Entire Agreement. This Agreement contains the entire understanding of the Company
and the Employee with respect to the subject matter hereof. 
 (f) Amendments and Waivers. This Agreement may not be
amended, modified or any provision hereof waived otherwise than by a written agreement executed by the parties hereto or their respective successors and legal representatives. The Employee’s or the Company’s failure to insist upon strict
compliance with any provision hereof shall not be deemed to be a waiver of such provision or any other provision hereof. 
 (g)
Assignment and Successors. 
 (i) This Agreement is personal to the Employee and without the prior written
consent of the Company shall not be assignable by the Employee otherwise than by will or the laws of descent and distribution. This Agreement shall inure to the benefit of and be enforceable by the Employee’s legal representatives. 

(ii) This Agreement shall inure to the benefit of and be binding upon the Company and its successors and assigns.

 (iii) The Company will require any successor (whether direct or indirect, by purchase, merger, consolidation
or otherwise) to all or substantially all of the business and/or assets of the Company to assume expressly and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such
succession had taken place. 
 [Signature Page to Follow] 
  

 4 

 IN WITNESS WHEREOF, the party hereto has executed this Change of Control Cash Severance
Agreement or caused this Agreement to be executed by a duly authorized representative, as of the date first written above. 
  

					
	BG MEDICINE, INC.:
		
	By:	 	/s/ Pieter Muntendam
		 	Name:	 	Pieter Muntendam, M.D.
		 	Title:	 	President and CEO
	
	EMPLOYEE:
		
	By:	 	/s/ C. Douglas White
		 	Name:	 	C. Douglas White
		 	Title:	 	EVP & General Manager, Diagnostics

  

 52001 Stock Option and Incentive Plan, as Amended

 Exhibit 10.15 
 BEYOND GENOMICS, INC. 
 2001 STOCK OPTION AND INCENTIVE
PLAN 
 Purpose and Eligibility 
 The purpose of this 2001 Stock Option and Incentive Plan (the “Plan”) of Beyond Genomics, Inc. (the “Company”) is to provide stock options and other equity interests in
the Company (each an “Award”) to employees, officers, directors, consultants and advisors of the Company and its Subsidiaries, all of whom are eligible to receive Awards under the Plan. Any person to whom an Award has been granted
under the Plan is called a “Participant”. Additional definitions are contained in Section 8. 
  

	2.	Administration 

 a.
Administration by Board of Directors. The Plan will be administered by the Board of Directors of the Company (the “Board”). The Board, in its sole discretion, shall have the authority to grant and amend Awards, to adopt,
amend and repeal rules relating to the Plan and to interpret and correct the provisions of the Plan and any Award. All decisions by the Board shall be final and binding on all interested persons. Neither the Company nor any member of the Board shall
be liable for any action or determination relating to the Plan. 
 b. Appointment of Committees. To the extent permitted
by applicable law, the Board may delegate any or all of its powers under the Plan to one or more committees or subcommittees of the Board (a “Committee”). All references in the Plan to the “Board” shall mean such
Committee or the Board. 
 c. Delegation to Executive Officers. To the extent permitted by applicable law, the Board may
delegate to one or more executive officers of the Company the power to grant Awards and exercise such other powers under the Plan as the Board may determine, provided that the Board shall fix the maximum number of Awards to be granted and the
maximum number of shares issuable to any one Participant pursuant to Awards granted by such executive officers. 
  

	3.	Stock Available for Awards 

 a. Number of Shares. Subject to adjustment under Section 3(c), the aggregate number of shares of Common Stock of the Company (the “Common Stock”) that may be issued pursuant to the Plan is 1,000,000 shares. If any
Award expires, or is terminated, surrendered or forfeited, in whole or in part, the unissued Common Stock covered by such Award shall again be available for the grant of Awards under the Plan. If shares of Common Stock issued pursuant to the Plan
are repurchased by, or are surrendered or forfeited to, the Company at no more than cost, such shares of Common Stock shall again be available for the grant of Awards under the Plan; provided, however, that the cumulative number of such
shares that may be so reissued under the Plan will not exceed 1,000,000 shares. Shares issued under the Plan may consist in whole or in part of authorized but unissued shares or treasury shares. 

 b. Per Participant Limit. Subject to adjustment under Section 3(c), no Participant
may be granted Awards during any one fiscal year to purchase more than 750,000 shares of Common Stock. 
 c. Adjustment to
Common Stock. In the event of any stock split, stock dividend, extraordinary cash dividend, recapitalization, reorganization, merger, consolidation, combination, exchange of shares, liquidation, spin-off, split-up, or other similar change in
capitalization or event, (i) the number and class of securities available for Awards under the Plan and the per Participant share limit, (ii) the number and class of securities, vesting schedule and exercise price per share subject to each
outstanding Option, (iii) the repurchase price per security subject to repurchase, and (iv) the terms of each other outstanding stock-based Award shall be adjusted by the Company (or substituted Awards may be made) to the extent the Board shall
determine, in good faith, that such an adjustment (or substitution) is appropriate. If Section 7(e)(i) applies for any event, this Section 3(c) shall not be applicable. 
  

	4.	Stock Options 

 a.
General. The Board may grant options to purchase Common Stock (each, an “Option”) and determine the number of shares of Common Stock to be covered by each Option, the exercise price of each Option and the conditions and
limitations applicable to the exercise of each Option and the Common Stock issued upon the exercise of each Option, including vesting provisions, repurchase provisions and restrictions relating to applicable federal or state securities laws, as it
considers advisable. 
 b. Incentive Stock Options. An Option that the Board intends to be an “incentive stock
option” as defined in Section 422 of the Code (an “Incentive Stock Option”) shall be granted only to employees of the Company and shall be subject to and shall be construed consistently with the requirements of Section 422 of
the Code. The Board and the Company shall have no liability if an Option or any part thereof that is intended to be an Incentive Stock Option does not qualify as such. An Option or any part thereof that does not qualify as an Incentive Stock Option
is referred to herein as a “Nonstatutory Stock Option.” 
 c. Exercise Price. The Board shall establish
the exercise price (or determine the method by which the exercise price shall be determined) at the time each Option is granted and specify it in the applicable option agreement. 
 d. Duration of Options. Each Option shall be exercisable at such times and subject to such terms and conditions as the Board may
specify in the applicable option agreement. 
 e. Exercise of Option. Options may be exercised only by delivery to the
Company of a written notice of exercise signed by the proper person together with payment in full as specified in Section 4(f) for the number of shares for which the Option is exercised. 
  

 2 

 f. Payment Upon Exercise. Common Stock purchased upon the exercise of an Option shall
be paid for by one or any combination of the following forms of payment: 
 (i) by check payable to the order of
the Company; 
 (ii) except as otherwise explicitly provided in the applicable option agreement, and only if the
Common Stock is then publicly traded, delivery of an irrevocable and unconditional undertaking by a creditworthy broker to deliver promptly to the Company sufficient funds to pay the exercise price, or delivery by the Participant to the Company of a
copy of irrevocable and unconditional instructions to a creditworthy broker to deliver promptly to the Company cash or a check sufficient to pay the exercise price; or 
 (iii) to the extent explicitly provided in the applicable option agreement, by (x) delivery of shares of Common Stock owned
by the Participant valued at fair market value (as determined by the Board or as determined pursuant to the applicable option agreement), (y) delivery of a promissory note of the Participant to the Company (and delivery to the Company by the
Participant of a check in an amount equal to the par value of the shares purchased), or (z) payment of such other lawful consideration as the Board may determine. 
  

	5.	Restricted Stock 

 a.
Grants. The Board may grant Awards entitling recipients to acquire shares of Common Stock, subject to (i) delivery to the Company by the Participant of a check in an amount at least equal to the par value of the shares purchased, and (ii) the
right of the Company to repurchase all or part of such shares at their issue price or other stated or formula price from the Participant in the event that conditions specified by the Board in the applicable Award are not satisfied prior to the end
of the applicable restriction period or periods established by the Board for such Award (each, a “Restricted Stock Award”). 
 b. Terms and Conditions. The Board shall determine the terms and conditions of any such Restricted Stock Award. Any stock certificates issued in respect of a Restricted Stock Award shall be
registered in the name of the Participant and, unless otherwise determined by the Board, deposited by the Participant, together with a stock power endorsed in blank, with the Company (or its designee). After the expiration of the applicable
restriction periods, the Company (or such designee) shall deliver the certificates no longer subject to such restrictions to the Participant or, if the Participant has died, to the beneficiary designated by a Participant, in a manner determined by
the Board, to receive amounts due or exercise rights of the Participant in the event of the Participant’s death (the “Designated Beneficiary”). In the absence of an effective designation by a Participant, Designated Beneficiary
shall mean the Participant’s estate. 
  

	6.	Other Stock-Based Awards 

 The Board shall have the right to grant other Awards based upon the Common Stock having such terms and conditions as the Board may determine, including, without limitation, the grant of shares based upon certain conditions, the grant of
securities convertible into Common Stock and the grant of stock appreciation rights, phantom stock awards or stock units. 
  

 3 

	7.	General Provisions Applicable to Awards 

 a. Transferability of Awards. Except as the Board may otherwise determine or provide in an Award, Awards shall not be sold, assigned, transferred, pledged or otherwise encumbered by the person to
whom they are granted, either voluntarily or by operation of law, except by will or the laws of descent and distribution, and, during the life of the Participant, shall be exercisable only by the Participant. References to a Participant, to the
extent relevant in the context, shall include references to authorized transferees. 
 b. Documentation. Each Award under
the Plan shall be evidenced by a written instrument in such form as the Board shall determine or as executed by an officer of the Company pursuant to authority delegated by the Board. Each Award may contain terms and conditions in addition to those
set forth in the Plan provided that such terms and conditions do not contravene the provisions of the Plan. 
 c.
Board Discretion. The terms of each type of Award need not be identical, and the Board need not treat Participants uniformly. 
 d. Termination of Status. The Board shall determine the effect on an Award of the disability, death, retirement, authorized leave of absence or other change in the employment or other status of a Participant and the extent to which,
and the period during which, the Participant, or the Participant’s legal representative, conservator, guardian or Designated Beneficiary, may exercise rights under the Award. 
 e. Acquisition of the Company 
 (i) Consquences of an Acquisition. 
 (A) Effect on
Options, Restricted Stock Awards and Other Stock-Based Awards. In addition to any acceleration provisions expressly provided in the applicable option agreement, stock restriction agreement or any other agreement between a Participant and the
Company in respect of an Award, upon consummation of an Acquisition (as defined below), the Board shall have the authority to accelerate the date(s) that (x) any outstanding Options shall become exercisable, (y) any Restricted Stock Awards then
outstanding shall become free of repurchase provisions, and (z) any other stock-based Awards shall become exercisable, realizable or vested, or shall become free of repurchase provisions, as the case may be. Upon consummation of an Acquisition, the
Board or the board of directors of the surviving or acquiring entity (as used in this Section 7(e)(i)(A), also the “Board”), shall, as to such outstanding Awards (on the same basis or on different bases, as the Board shall specify),
make appropriate provision for the continuation of such Awards by the Company or the assumption of such Awards by the surviving or acquiring entity and by substituting on an equitable basis for the shares then subject to such Awards either (a) the
consideration payable with respect to the

  

 4 

 
outstanding shares of Common Stock in connection with the Acquisition, (b) shares of stock of the surviving or acquiring corporation or (c) such other securities as the Board deems appropriate,
the fair market value of which (as determined by the Board in its sole discretion) shall not materially differ from the fair market value of the shares of Common Stock subject to such Awards immediately preceding the Acquisition. In addition to or
in lieu of the foregoing, with respect to outstanding Options, the Board may, upon written notice to the affected Participants, provide that one or more Options then outstanding shall become immediately exercisable in full and that such Options must
be exercised within a specified number of days of the date of such notice, at the end of which period such Options shall terminate; or provide that one or more Options then outstanding shall become immediately exercisable in full and shall be
terminated in exchange for a cash payment equal to the excess of the fair market value (as determined by the Board in its sole discretion) for the shares subject to such Options over the exercise price thereof. 
 (B) Acquisition Defined. An “Acquisition” shall mean: (x) the sale of the Company by merger in which
the shareholders of the Company in their capacity as such no longer own a majority of the outstanding equity securities of the Company (or its successor); or (y) any sale of all or substantially all of the assets or capital stock of the Company
(other than in a spin-off or similar transaction) or (z) any other acquisition of the business of the Company, as determined by the Board. 
 (ii) Assumption of Options Upon Certain Events. In connection with a merger or consolidation of an entity with the Company or the acquisition by the Company of property or stock of an entity, the
Board may grant Awards under the Plan in substitution for stock and stock-based awards issued by such entity or an affiliate thereof. The substitute Awards shall be granted on such terms and conditions as the Board considers appropriate in the
circumstances. 
 (iii) Pooling-of Interests-Accounting. If the Company proposes to engage in an
Acquisition intended to be accounted for as a pooling-of-interests, and in the event that the provisions of this Plan or of any Award hereunder, or any actions of the Board taken in connection with such Acquisition, are determined by the
Company’s or the acquiring company’s independent public accountants to cause such Acquisition to fail to be accounted for as a pooling-or-interests, then such provisions or actions shall be amended or rescinded by the Board, without the
consent of any Participant, to be consistent with pooling-of-interests accounting treatment for such Acquisition. 
 (iv) Parachute Awards. Notwithstanding the provisions of Section 7(e)(i)(A), if, in connection with an Acquisition described therein, a tax under Section 4999 of the Code would be imposed on the Participant (after taking into account
the exceptions set forth in Sections 280G(b)(4) and 280G(b)(5) of the Code), then the number of Awards which shall become exercisable, realizable or vested as provided in such section shall be reduced (or delayed), to the minimum extent necessary,
so that no such tax would be imposed on the Participant (the Awards not becoming so accelerated, realizable or vested, the “Parachute Awards”); provided, however, that if the “aggregate present value” of the
Parachute Awards would exceed the tax that, but for this sentence, would be imposed on the Participant under

  

 5 

 
Section 4999 of the Code in connection with the Acquisition, then the Awards shall become immediately exercisable, realizable and vested without regard to the provisions of this sentence. For
purposes of the preceding sentence, the “aggregate present value” of an Award shall be calculated on an after-tax basis (other than taxes imposed by Section 4999 of the Code) and shall be based on economic principles rather than the
principles set forth under Section 280G of the Code and the regulations promulgated thereunder. All determinations required to be made under this Section 7(e)(iv) shall be made by the Company. 
 f. Withholding. Each Participant shall pay to the Company, or make provisions satisfactory to the Company for payment of, any taxes
required by law to be withheld in connection with Awards to such Participant no later than the date of the event creating the tax liability. The Board may allow Participants to satisfy such tax obligations in whole or in part by transferring shares
of Common Stock, including shares retained from the Award creating the tax obligation, valued at their fair market value (as determined by the Board or as determined pursuant to the applicable option agreement). The Company may, to the extent
permitted by law, deduct any such tax obligations from any payment of any kind otherwise due to a Participant. 
 g.
Amendment of Awards. The Board may amend, modify or terminate any outstanding Award including, but not limited to, substituting therefor another Award of the same or a different type, changing the date of exercise or realization, and
converting an Incentive Stock Option to a Nonstatutory Stock Option, provided that, except as otherwise provided in Section 7(e)(iii), the Participant’s consent to such action shall be required unless the Board determines that the
action, taking into account any related action, would not materially and adversely affect the Participant. 
 h. Conditions
on Delivery of Stock. The Company will not be obligated to deliver any shares of Common Stock pursuant to the Plan or to remove restrictions from shares previously delivered under the Plan until (i) all conditions of the Award have been met or
removed to the satisfaction of the Company, (ii) in the opinion of the Company’s counsel, all other legal matters in connection with the issuance and delivery of such shares have been satisfied, including any applicable securities laws and any
applicable stock exchange or stock market rules and regulations, and (iii) the Participant has executed and delivered to the Company such representations or agreements as the Company may consider appropriate to satisfy the requirements of any
applicable laws, rules or regulations. 
 i. Acceleration. The Board may at any time provide that any Options shall
become immediately exercisable in full or in part, that any Restricted Stock Awards shall be free of some or all restrictions, or that any other stock-based Awards may become exercisable in full or in part or free of some or all restrictions or
conditions, or otherwise realizable in full or in part, as the case may be, despite the fact that the foregoing actions may (i) cause the application of Sections 280G and 4999 of the Code if a change in control of the Company occurs, or (ii)
disqualify all or part of the Option as an Incentive Stock Option. 
  

 6 

	8.	Miscellaneous 

 a.
Definitions. 
 (i) “Company,” for purposes of eligibility under the Plan, shall include
any present or future subsidiary corporations of Beyond Genomics, Inc., as defined in Section 424(f) of the Code (a “Subsidiary”), and any present or future parent corporation of Beyond Genomics, Inc., as defined in Section 424(e)
of the Code. For purposes of Awards other than Incentive Stock Options, the term “Company” shall include any other business venture in which the Company has a direct or indirect significant interest, as determined by the Board in
its sole discretion. 
 (ii) “Code” means the Internal Revenue Code of 1986, as amended, and any
regulations promulgated thereunder. 
 (iii) “employee” for purposes of eligibility under the
Plan (but not for purposes of Section 4(b) or Section 7(e)(i)(A)) shall include a person to whom an offer of employment has been extended by the Company. 
 b. No Right To Employment or Other Status. No person shall have any claim or right to be granted an Award, and the grant of an Award shall not be construed as giving a Participant the right to
continued employment or any other relationship with the Company. The Company expressly reserves the right at any time to dismiss or otherwise terminate its relationship with a Participant free from any liability or claim under the Plan. 

c. No Rights As Stockholder. Subject to the provisions of the applicable Award, no Participant or Designated Beneficiary shall
have any rights as a stockholder with respect to any shares of Common Stock to be distributed with respect to an Award until becoming the record holder thereof. 
 d. Effective Date and Term of Plan. The Plan shall become effective on the date on which it is adopted by the Board. No Awards shall be granted under the Plan after the completion of ten years from
the date on which the Plan was adopted by the Board, but Awards previously granted may extend beyond that date. 
 e.
Amendment of Plan. The Board may amend, suspend or terminate the Plan or any portion thereof at any time. 
 f.
Governing Law. The provisions of the Plan and all Awards made hereunder shall be governed by and interpreted in accordance with the laws of the Commonwealth of Massachusetts, without regard to any applicable conflicts of law. 
 Adopted by the Board of Directors on 
 June 6, 2001 
 Approved by the stockholders on 
 March 20, 2002 
  

 7 

 AMENDMENT NO. 1 TO THE BEYOND GENOMICS, INC. 2001 STOCK OPTION AND INCENTIVE PLAN 

 This Amendment No. 1 (the “Amendment”) to the Beyond Genomics, Inc. 2001 Stock Option and Incentive Plan dated June
6, 2001 (the “Plan”) is made in accordance with the provisions of Section 8(e) of the Plan. Any capitalized terms not defined herein shall have the meaning set forth in the Plan. 
  

	A.	Section 3(a) of the Plan shall be amended and replaced in its entirety with the following: 

 “Number of Shares. Subject to adjustment under Section 3(c), the aggregate number of shares of Common Stock of the Company (the
“Common Stock”) that may be issued pursuant to the Plan is 3,500,000 shares. If any Award expires, or is terminated, surrendered or forfeited, in whole or in part, the unissued Common Stock covered by such Award shall again be
available for the grant of Awards under the Plan. If shares of Common Stock issued pursuant to the Plan are repurchased by, or are surrendered or forfeited to, the Company at no more than cost, such shares of Common Stock shall again be available
for the grant of Awards under the Plan; provided, however, that the cumulative number of such shares that may be so reissued under the Plan will not exceed 3,500,000 shares. Shares issued under the Plan may consist in whole or in part of
authorized but unissued shares or treasury shares.” 
  

	B.	Section 3(b) shall be amended and replaced in its entirety with the following: 

 “Per Participant Limit. Subject to adjustment under Section 3(c), no Participant may be granted Awards during any one fiscal year
to purchase more than 2,625,000 shares of Common Stock.” 
 Except as expressly set forth herein, no other terms or
provisions of the Plan are amended or modified, and all such provisions and terms are hereby ratified and confirmed in all respects. 
 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

 IN WITNESS WHEREOF, the undersigned has executed this Amendment this 26th day of April,
2002. 
  

			
	BEYOND GENOMICS, INC.
		
	By:	 	/s/ N. Stephen Ober
		 	Name: N. Stephen Ober, MD
		 	Title:   President

 Amendment No. 2 to the 
 BEYOND GENOMICS, INC. 
 2001 Stock Option and
Incentive Plan 
 This Amendment No. 2 (the “Amendment”) to the Beyond Genomics, Inc. 2001 Stock Option and
Incentive Plan dated December 19, 2003 (the “Plan”) is made in accordance with the provisions of Section 8(e) of the Plan. Any capitalized terms not defined herein shall have the meaning set forth in the Plan. 
  

	A.	Section 3(a) of the Plan shall be amended and replaced in its entirety with the following 

 “Number of Shares. Subject to adjustment under Section 3(c), the aggregate number of shares of Common Stock of the Company (the
“Common Stock”) that may be issued pursuant to the Plan is 4,000,000 shares. If any Award expires, or is terminated, surrendered or forfeited, in whole or in part, the unissued Common Stock covered by such Award shall again be
available for the grant of Awards under the Plan. If shares of Common Stock issued pursuant to the Plan are repurchased by, or are surrendered or forfeited to, the Company at no more than cost, such shares of Common Stock shall again be available
for the grant of Awards under the Plan; provided, however, that the cumulative number of such shares that may be so reissued under the Plan will not exceed 4,000,000 shares. Shares issued under the Plan may consist in whole or in part of
authorized but unissued shares or treasury shares.” 
  

	B.	Section 3(b) shall be amended and replaced in its entirety with the following: 

 “Per Participant Limit. Subject to adjustment under Section 3(c), no Participant may be granted Awards during any one fiscal year
to purchase more than 3,000,000 shares of Common Stock.” 
 Except as expressly set forth herein, no other terms or
provisions of the Plan are amended or modified, and all such provisions and terms are hereby ratified and confirmed in all respects. 
 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

 IN WITNESS WHEREOF, the undersigned has executed this Amendment this 19
th day of December, 2003. 
  

			
	BEYOND GENOMICS, INC.
		
	By:	 	/s/ N. Stephen Ober
		 	Name: N. Stephen Ober
		 	Title:   President

  

 2 

 Amendment No. 3 to the 
 BEYOND GENOMICS, INC. 
 2001 Stock Option and
Incentive Plan 
 This Amendment No. 3 (the “Amendment”) to the Beyond Genomics, Inc. 2001 Stock Option and
Incentive Plan dated March 2, 2004 (the “Plan”) is made in accordance with the provisions of Section 8(e) of the Plan. Any capitalized terms not defined herein shall have the meaning set forth in the Plan. 
  

	A.	Section 3(a) of the Plan shall be amended and replaced in its entirety with the following: 

 “Number of Shares. Subject to adjustment under Section 3(c), the aggregate number of shares of Common Stock of the Company (the
“Common Stock”) that may be issued pursuant to the Plan is 7,000,000 shares. If any Award expires, or is terminated, surrendered or forfeited, in whole or in part, the unissued Common Stock covered by such Award shall again be
available for the grant of Awards under the Plan. If shares of Common Stock issued pursuant to the Plan are repurchased by, or are surrendered or forfeited to, the Company at no more than cost, such shares of Common Stock shall again be available
for the grant of Awards under the Plan; provided, however, that the cumulative number of such shares that may be so reissued under the Plan will not exceed 7,000,000 shares. Shares issued under the Plan may consist in whole or in part of
authorized but unissued shares or treasury shares.” 
  

	B.	Section 3(b) shall be amended and replaced in its entirety with the following: 

 “Per Participant Limit. Subject to adjustment under Section 3(c), no Participant may be granted Awards during any one fiscal year
to purchase more than 5,250,000 shares of Common Stock.” 
 Except as expressly set forth herein, no other terms or
provisions of the Plan are amended or modified, and all such provisions and terms are hereby ratified and confirmed in all respects. 
 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

 IN WITNESS WHEREOF, the undersigned has executed this Amendment this 2
nd day of March, 2004. 
  

			
	BEYOND GENOMICS, INC.
		
	By:	 	/s/ Muzammil Mansuri
		 	Name: Muzammil Mansuri, Ph.D
		 	Title:   Executive Chairman

  

 2 

 AMENDMENT NO. 4 TO THE 
 BG MEDICINE, INC. 
 2001 STOCK OPTION AND INCENTIVE
PLAN 
 This Amendment No. 4 (the “Amendment”) to the BG Medicine, Inc. 2001 Stock Option and Incentive Plan,
as amended (the “Plan”) is made in accordance with the provisions of Section 8(e) of the Plan. Any capitalized terms not defined herein shall have the meaning set forth in the Plan. 
 Section 3(a) of the Plan shall be amended and replaced in its entirety with the following: 
 “Number of Shares. Subject to adjustment under Section 3(c), the aggregate number of shares of Common Stock of the Company
(the “Common Stock”) that may be issued pursuant to the Plan is 8,000,000 shares. If any Award expires, or is terminated, surrendered or forfeited, in whole or in part, the unissued Common Stock covered by such Award shall again be
available for the grant of Awards under the Plan. If shares of Common Stock issued pursuant to the plan are repurchased by, or are surrendered or forfeited to, the Company at no more than cost, such shares of Common Stock shall again be available
for the grant of Awards under the plan; provided, however, that the cumulative number of such shares that may be so reissued under the Plan will not exceed 8,000,000 shares. Shares issued under the Plan may consist in whole or in part of authorized
but unissued shares or treasury shares.” 
 Except as expressly set forth herein, no other terms or provisions of the Plan
are amended or modified, and all such provisions and terms are hereby ratified and confirmed in all respects. 
  

											
	 Approved by the Board if Directors:
	  	June 8, 2007	  		  		  		  	
	 Approved by the Stockholders:
	  	October 31, 2007	  		  		  		  	

 AMENDMENT NO. 5 TO THE 
 BG MEDICINE, INC. 
 2001 STOCK OPTION AND INCENTIVE
PLAN 
 This Amendment No. 5 (the “Amendment”) to the BG Medicine, Inc. 2001 Stock Option and
Incentive Plan, as amended (the “Plan”) is made in accordance with the provisions of Section 8(e) of the Plan. Any capitalized terms not defined herein shall have the meaning set forth in the Plan. 
 Section 3(a) of the Plan shall be amended and replaced in its entirety with the following: 
 “Number of Shares. Subject to adjustment under Section 3(c), the aggregate number of shares of Common Stock of the Company
(the “Common Stock”) that may be issued pursuant to the Plan is 4,488,317 shares. Amendment No. 5 to the Plan increases the total number of securities available for Awards under the Plan by 750,000 shares. Prior to Amendment
No. 5, the aggregate number of securities that had been available for Awards under the Plan had been 3,738,317 shares, as a result of there having been 8,000,000 shares reserved under the Plan immediately prior to the reverse stock split that
took place on October 31, 2007, the effect of which was that every 2.14 of the then issued and outstanding shares of Common Stock of the Company were changed, combined and reclassified into one whole share of Common Stock of the Company.
Pursuant to Section 3(c) of the Plan, the reverse stock split on October 31, 2007 also resulted in an adjustment to the number of securities then available for Awards under the Plan and the number of securities subject to each outstanding
Option under the Plan, which caused the pre-split number of 8,000,000 to become a post-split number of 3,738,317. If any Award expires, or is terminated, surrendered or forfeited, in whole or in part, the unissued Common Stock covered by such Award
shall again be available for the grant of Awards under the Plan. If shares of Common Stock issued pursuant to the plan are repurchased by, or are surrendered or forfeited to, the Company at no more than cost, such shares of Common Stock shall again
be available for the grant of Awards under the plan; provided, however, that the cumulative number of such shares that may be so reissued under the Plan will not exceed 4,488,317 shares. Shares issued under the Plan may consist in whole or in part
of authorized but unissued shares or treasury shares.” 
 Except as expressly set forth herein, no other terms or
provisions of the Plan are amended or modified, and all such provisions and terms are hereby ratified and confirmed in all respects. 
  

									
	 Approved by the Compensation Committee:
	 	September 16, 2008	  		  		  	
	 Ratified by the Board of Directors:
	 	October 30, 2008	  		  		  	
	 Approved by Stockholders:
	 	September 10, 2009	  		  		  	

 AMENDMENT NO. 6 TO THE 
 BG MEDICINE, INC. 
 2001 STOCK OPTION AND INCENTIVE
PLAN 
 This Amendment No. 6 (the “Amendment”) to the BG Medicine, Inc. 2001 Stock Option and
Incentive Plan, as amended (the “Plan”) is made in accordance with the provisions of Section 8(e) of the Plan. Any capitalized terms not defined herein shall have the meaning set forth in the Plan. 
 Section 3(a) of the Plan shall be amended and replaced in its entirety with the following: 
 “Number of Shares. Subject to adjustment under Section 3(c), the aggregate number of shares of Common Stock of the Company
(the “Common Stock”) that may be issued pursuant to the Plan is 4,988,317 shares. Amendment No. 6 to the Plan increases the total number of securities available for Awards under the Plan by 500,000 shares. Prior to Amendment
No. 6, the aggregate number of securities that had been available for Awards under the Plan had been 4,488,317 shares. If any Award expires, or is terminated, surrendered or forfeited, in whole or in part, the unissued Common Stock covered by
such Award shall again be available for the grant of Awards under the Plan. If shares of Common Stock issued pursuant to the plan are repurchased by, or are surrendered or forfeited to, the Company at no more than cost, such shares of Common Stock
shall again be available for the grant of Awards under the plan; provided, however, that the cumulative number of such shares that may be so reissued under the Plan will not exceed 4,988,317 shares. Shares issued under the Plan may consist in whole
or in part of authorized but unissued shares or treasury shares.” 
 Except as expressly set forth herein, no other terms
or provisions of the Plan are amended or modified, and all such provisions and terms are hereby ratified and confirmed in all respects. 
  

											
	 Approved by the Compensation Committee:
	  	April 7, 2009	  		  		  		  	
	 Ratified by the Board of Directors:
	  	June 30, 2009	  		  		  		  	
	 Approved by Stockholders:
	  	September 10, 2009	  		  		  		  	

 AMENDMENT NO. 7 TO THE 
 BG MEDICINE, INC. 
 2001 STOCK OPTION AND INCENTIVE
PLAN 
 This Amendment No. 7 (the “Amendment”) to the BG Medicine, Inc. 2001 Stock Option and
Incentive Plan, as amended (the “Plan”) is made in accordance with the provisions of Section 8(e) of the Plan. Any capitalized terms not defined herein shall have the meaning set forth in the Plan. 
 Section 3(a) of the Plan shall be amended and replaced in its entirety with the following: 
 “Number of Shares. Subject to adjustment under Section 3(c), the aggregate number of shares of Common Stock of the Company
(the “Common Stock”) that may be issued pursuant to the Plan is 5,188,317 shares. Amendment No. 7 to the Plan increases the total number of securities available for Awards under the Plan by 200,000 shares. Prior to Amendment
No. 7, the aggregate number of securities that had been available for Awards under the Plan had been 4,988,317 shares. If any Award expires, or is terminated, surrendered or forfeited, in whole or in part, the unissued Common Stock covered by
such Award shall again be available for the grant of Awards under the Plan. If shares of Common Stock issued pursuant to the plan are repurchased by, or are surrendered or forfeited to, the Company at no more than cost, such shares of Common Stock
shall again be available for the grant of Awards under the plan; provided, however, that the cumulative number of such shares that may be so reissued under the Plan will not exceed 5,188,317 shares. Shares issued under the Plan may consist in whole
or in part of authorized but unissued shares or treasury shares.” 
 Except as expressly set forth herein, no other terms
or provisions of the Plan are amended or modified, and all such provisions and terms are hereby ratified and confirmed in all respects. 
  

							
	 Approved by the Compensation Committee:
	  	November 25, 2009	  		  	
	 Ratified by the Board of Directors:
	  	December 17, 2009

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00167-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00167-of-00352.parquet"}]]